About Us - CiRC Biosciences

CiRC Biosciences

CiRC is developing cellular reprogramming therapies for degenerative diseases. Current treatment options for many of these conditions cannot restore function.

CiRC’s platform converts fibroblasts directly into specific neurons lost in degenerative disease. Current programs target dopaminergic neurons in Parkinson’s disease, GABAergic interneurons in refractory epilepsy, and orexin neurons in treatment-resistant narcolepsy. The platform builds on prior scientific and manufacturing advances in retinal cell replacement.

CiRC is a Paragon Biosciences portfolio company.

View available career opportunities here

CiRC Biosciences

CiRC is developing cellular reprogramming therapies for degenerative eye and brain diseases. Current treatment options for many of these conditions cannot restore function.

In preclinical development, CiRC generated photoreceptor and dopaminergic neuron precursor cells with the potential to treat a wide range of degenerative diseases. The platform can generate multiple cell types using small molecules and growth factors to transform fibroblasts into needed cells.

CiRC is a Paragon Biosciences portfolio company.

View available career opportunities here

Neurology

CiRC’s current programs target three neurological conditions defined by progressive loss of specific neurons with no disease-modifying treatments.

In Parkinson's disease, the loss of dopaminergic neurons causes irreversible motor impairment. More than ten million people worldwide live with the disease. Current treatments manage symptoms — none halt or reverse progression.

In refractory epilepsies, seizures persist despite available medications. For some patients, loss of GABAergic interneurons drives seizure activity. CBS-104 targets this deficiency.

In treatment-resistant narcolepsy, the loss of orexin-producing neurons disrupts sleep-wake regulation. CBS-105 aims to restore orexin neuron function directly.

Ophthalmology

Ophthalmology

CiRC's platform can potentially alter the trajectory of vision loss for patients with degenerative retinal diseases. Retinitis pigmentosa and geographic atrophy affect approximately five million patients in the United States, with very limited treatment options available today.

CiRC's retinal program – CBS-101 in retinitis pigmentosa – established proof of concept for the direct reprogramming platform and informed the manufacturing approach and scale now being applied to neurology programs.

Neurology

CiRC Biosciences

CiRC is developing cellular reprogramming therapies for degenerative eye and brain diseases. Current treatment options for many of these conditions cannot restore function.

CiRC’s platform converts fibroblasts directly into specific neurons lost in degenerative disease. Current programs target dopaminergic neurons in Parkinson’s disease, GABAergic interneurons in refractory epilepsy, and orexin neurons in treatment-resistant narcolepsy. The platform builds on prior scientific and manufacturing advances in retinal cell replacement.

CiRC is a Paragon Biosciences portfolio company.

Neurology

CiRC’s current programs target three neurological conditions defined by progressive loss of specific neurons with no disease-modifying treatments.

In Parkinson's disease, the loss of dopaminergic neurons causes irreversible motor impairment. More than ten million people worldwide live with the disease. Current treatments manage symptoms — none halt or reverse progression.

In refractory epilepsies, seizures persist despite available medications. For some patients, loss of GABAergic interneurons drives seizure activity. CBS-104 targets this deficiency.

In treatment-resistant narcolepsy, the loss of orexin-producing neurons disrupts sleep-wake regulation. CBS-105 aims to restore orexin neuron function directly.

Ophthalmology

Ophthalmology

CiRC's platform can potentially alter the trajectory of vision loss for patients with degenerative retinal diseases. Retinitis pigmentosa and geographic atrophy affect approximately five million patients in the United States, with very limited treatment options available today.

CiRC's retinal program – CBS-101 in retinitis pigmentosa – established proof of concept for the direct reprogramming platform and informed the manufacturing approach and scale now being applied to neurology programs.

Neurology

Neurology

CiRC’s current programs target three neurological conditions defined by progressive loss of specific neurons with no disease-modifying treatments.

In Parkinson's disease, the loss of dopaminergic neurons causes irreversible motor impairment. More than ten million people worldwide live with the disease. Current treatments manage symptoms — none halt or reverse progression.

In refractory epilepsies, seizures persist despite available medications. For some patients, loss of GABAergic interneurons drives seizure activity. CBS-104 targets this deficiency.

In treatment-resistant narcolepsy, the loss of orexin-producing neurons disrupts sleep-wake regulation. CBS-105 aims to restore orexin neuron function directly.

Ophthalmology

Neurology

Ophthalmology

CiRC's platform can potentially alter the trajectory of vision loss for patients with degenerative retinal diseases. Retinitis pigmentosa and geographic atrophy affect approximately five million patients in the United States, with very limited treatment options available today.

CiRC's retinal program – CBS-101 in retinitis pigmentosa – established proof of concept for the direct reprogramming platform and informed the manufacturing approach and scale now being applied to neurology programs.